Search

Theophilus J Gana

from Leesburg, VA
Age ~69
Get Report
Also known as:
Theophilus Jones Gana, Theodore J Gana, Theo Philus Gana, Drtheophilus Gana
Phone and address:
1627 Chickasaw Pl NE, Leesburg, VA 20176
(703) 669-8055
Related to:
Theo Gana
Connected to:
Alvaro Gana, 49Anna P Gana, 40Hassan B Gana, 41Jeannette T Gana, 69Kristy L Gana, 41Pamela A Gana, 53Sheldon J Gana, 52Shirley T Gana, 79Peter P Ganabathi, 42Maria L Ganac, 48

Theophilus Gana Phones & Addresses

  • 1627 Chickasaw Pl NE, Leesburg, VA 20176 (703) 669-8055
  • 200 Lawson Rd, Leesburg, VA 20175 (703) 669-5674 (703) 669-8055
  • 1504 Shields Ter, Leesburg, VA 20176 (703) 669-8055
  • 1188 Cambria Ter NE, Leesburg, VA 20176
  • 605 Howitzer Ter NE, Leesburg, VA 20176
  • Annandale, VA
  • 20415 Elm Grove Ter, Ashburn, VA 20147 (703) 723-5991
  • Chantilly, VA

Business Records

Name / Title
Company / Classification
Phones & Addresses
Theophilus Gana
Principal
Gee Pharma LLC
Nonclassifiable Establishments
200 Lawson Rd SE, Leesburg, VA 20175
Theophilus Gana
Principal
Biopharmatech Consulting Inc
Business Consulting Services
200 Lawson Rd SE, Leesburg, VA 20175

Publications

Us Patents

Methods For Treating Vasomotor Symptoms Using Gaba Analogs In A Gastric Retentive Dosage Form

View page
US Patent:
8329750, Dec 11, 2012
Filed:
Feb 10, 2009
Appl. No.:
12/368907
Inventors:
Bret Berner - Half Moon Bay CA, US
Sui Yuen Eddie Hou - Foster City CA, US
Theophilus J. Gana - Leesburg VA, US
Marilou S. Cramer - Redwood City CA, US
Carl A. Pelzel - Pleasanton CA, US
Assignee:
Depomed, Inc. - Menlo Park CA
International Classification:
A61K 31/195
US Classification:
514561, 514557, 514554
Abstract:
Methods for treating vasomotor symptoms associated with menopause are described.

Gastric Retentive Gabapentin Dosage Forms And Methods For Using Same

View page
US Patent:
8592481, Nov 26, 2013
Filed:
Dec 7, 2012
Appl. No.:
13/707961
Inventors:
Sui Yuen Eddie Hou - Foster City CA, US
Theophilus J. Gana - Leesburg VA, US
Marilou S. Cramer - Redwood City CA, US
Assignee:
Depomed, Inc. - Newark CA
International Classification:
A61K 31/195
A61K 9/22
A61K 9/52
US Classification:
514561, 424457, 424468
Abstract:
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen.

Chronotherapeutic Diltiazem Formulations And The Administration Thereof

View page
US Patent:
20040176352, Sep 9, 2004
Filed:
Sep 9, 2003
Appl. No.:
10/657752
Inventors:
Kenneth Albert - Mt. Kisco NY, US
Theophilus Gana - Leesburg VA, US
Paul Maes - Potomac MD, US
International Classification:
A61K031/553
US Classification:
514/211070
Abstract:
A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cof Diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.

Gastric Retentive Gabapentin Dosage Forms And Methods For Using Same

View page
US Patent:
20070184104, Aug 9, 2007
Filed:
Dec 29, 2006
Appl. No.:
11/648134
Inventors:
Bret Berner - Half Moon Bay CA, US
Sui Yuen Eddie Hou - Foster City CA, US
Theophilus Gana - Leesburg VA, US
Marilou Cramer - Redwood City CA, US
Assignee:
Depomed, Inc. - Menlo Park CA
International Classification:
A61K 9/22
A61K 31/195
A61K 9/52
US Classification:
424457000, 424468000, 514217000, 514242000, 514282000, 514385000, 514561000
Abstract:
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen.

Chronotherapeutic Diltiazem Formulations And The Administration Thereof

View page
US Patent:
20090118256, May 7, 2009
Filed:
Dec 7, 2007
Appl. No.:
11/952343
Inventors:
Kenneth Stephen ALBERT - Mt. Kisco NY, US
Theophilus Jones Gana - Leesburg VA, US
Paul Maes - Potomac MD, US
Assignee:
BIOVAIL LABORATORIES INTERNATIONAL S.R.L. - St. Michael
International Classification:
A61K 31/554
A61P 9/10
US Classification:
51421107
Abstract:
A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.

Gastric Retentive Gabapentin Dosage Forms And Methods For Using Same

View page
US Patent:
20090176882, Jul 9, 2009
Filed:
Dec 9, 2008
Appl. No.:
12/331184
Inventors:
Bret Berner - Half Moon Bay CA, US
Sui Yuen Eddie Hou - Foster City CA, US
Theophilus J. Gana - Leesburg VA, US
Marilou S. Cramer - Redwood City CA, US
Assignee:
Depomed, Inc. - Menlo Park CA
International Classification:
A61K 31/195
US Classification:
514561
Abstract:
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin treatment. In addition to the foregoing, the gastric retentive gabapentin dosages forms also exhibit decreased blood plasma concentrations and increased bioavailability throughout the dosing regimen.

Methods For Treating Vasomotor Symptoms Using Gaba Analogs In A Gastric Retentive Dosage Form

View page
US Patent:
20130158121, Jun 20, 2013
Filed:
Nov 27, 2012
Appl. No.:
13/686865
Inventors:
Sui Yuen Eddie Hou - Foster City CA, US
Theophilus J. Gana - Leesburg VA, US
Marilou S. Cramer - Redwood City CA, US
Carl A. Pelzel - Pleasanton CA, US
Assignee:
Depomed, Inc. - Menlo Park CA
International Classification:
A61K 31/195
US Classification:
514561
Abstract:
Methods for treating vasomotor symptoms associated with menopause are described.

Thylakoid Extract Composition And Formulation For The Treatment Of Inflammatory Bowel Disease

View page
US Patent:
20210128659, May 6, 2021
Filed:
Aug 20, 2020
Appl. No.:
16/998004
Inventors:
- Montmagny CA, US
Theophilus J. Gana - Leesburg VA, US
Nathalie Boucher - Trois-Rivieres, CA
International Classification:
A61K 36/21
A61K 9/00
A61K 9/19
A61K 31/015
A61K 31/409
A61K 31/555
A61K 31/065
A61P 1/00
A61K 9/02
A61K 9/08
A61K 47/06
A61K 47/10
A61K 47/14
A61K 47/26
A61M 31/00
Abstract:
Use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of inflammatory bowel disease, and method for the treatment thereof. The inflammatory bowel disease may comprise several diseases associated with inflammation of the small intestine, large intestine (colon), rectum or anus (anal sphincter), and may be particularly selected from ulcerative colitis and Crohn's disease.
Control profile
Theophilus J Gana from Leesburg, VA, age ~69 Get Report